Business Wire

Spirit Semiconductor Expanding Theale Headquarters and Opening Second Office in Leeds, UK

Share

Spirit Semiconductor, an innovator in high-performance radio frequency solutions, today announced it will be moving to a new headquarters in Theale, U.K. and will be opening a new satellite office in Leeds, U.K. to tap into the strong radio frequency (RF) monolithic microwave integrated circuit (MMIC) and filter engineering talent in Northern England. The expansion comes on the heels of swift customer adoption and deployment of Spirit Semiconductor’s technology for 5G massive multiple-input and multiple-output (mMIMO) and small cell base stations.

Since the company’s inception in 2020, it has experienced rapid growth, developing a core team of 15 people in less than one year. Located in one of the U.K.’s technology hotbeds, the new office is five times larger than current Spirit headquarters, boasting 9,000 square feet of office space. The new Leeds office will support the company’s plans to expand its product portfolio and enter into other high growth markets.

“When Spirit Semiconductor was founded last year, we were solely focused on creating cutting edge radio frequency products for 5G mMIMO. Currently, our products are being evaluated by customers but the feedback we have received so far has been hugely positive and really provides us with the encouragement we need to branch out into other markets,” said Mark Moffat, managing director of Spirit Semiconductor. “At this rate, we are targeting 65% growth in 2021. This is only the beginning for our company, and I could not be more excited to see what the next year brings by way of innovation and expansion.”

“Massive MIMO architectures change the fundamental building blocks of the RF chain dramatically,” commented Joe Madden, chief analyst at Mobile Experts. “We are experiencing very rapid market growth for some RF components as the base station design adapts to 32T and 64T variations of massive MIMO, with tight performance requirements for RFICs to support a wide range of applications.”

Spirit Semiconductor is looking for the semiconductor industry’s top talent. The company is currently hiring for several positions: principal filter design engineer, principal MMIC design engineer, senior MMIC design engineer and senior analog IC design engineer. For additional information, contact Luke Ord at IC Resources, luke.ord@ic-resources.com, +44 118 907 3070.

“IC Resources is excited to be helping Spirit Semiconductor to identify the right talent to fuel its impressive growth,” commented Kathy Campling, client services director at IC Resources. “Spirit’s strong business plan, exciting product roadmap and generous benefits package are an attractive proposition to potential employees.”

About Spirit Semiconductor Ltd.

Spirit Semiconductor Ltd. is a United Kingdom based company, founded by experts in the radio frequency (RF) semiconductor industry. We are focused on developing high-performance RF products to support the rapid roll out of 5G massive MIMO (mMIMO), small cell base stations and other markets requiring high performance solutions. At Spirit Semiconductor our approach is intelligent innovation, fast implementation and strong team collaboration. We are an aggressive, fast-moving group that is focused on developing compelling products that meet our customers’ needs and timescales, while maintaining a strong team ethic and collaborative spirit. We believe in developing a balanced team that has all levels of experience and fostering an environment where everyone has the opportunity to learn and grow. To learn more, visit www.spiritsemiconductor.com.

Contact information

Olivia Metcalfe
Townsend Team
olivia@townsendteam.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RoboSense Teams Up With Webasto On Smart Roof Module With Integrated MEMS LiDAR23.4.2021 20:00:00 CEST | Press release

During the Shanghai Auto Show, RoboSense (https://robosense.ai/), a smart and automotive LiDAR system provider, and Webasto (https://www.webasto-group.com/), the global Top 100 automotive supplier and market leader for roof systems, announced cooperation on the Smart Roof Sensor Module that integrated with RoboSense automotive-grade MEMS LiDAR RS-LiDAR-M1 for Level 3 to Level 5 autonomous driving vehicles, largely simplifying the structure and mounting process of conventional sensor sets of self-driving vehicles and ensures advanced safety perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005484/en/ The M1 is seamlessly embedded into Webasto Roof Sensor Module (Photo: Business Wire) Through this strategic cooperation, Webasto is committed to seamlessly embedding the RoboSense M1, camera and other sensor systems to the panoramic roof of vehicles to provide safer and more reliable environment perception informat

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 202123.4.2021 16:05:00 CEST | Press release

LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021. Tralokinumab is a high affinity, human monoclonal antibody that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.2,3 It is an investigational therapy in clinical development, and its safety and efficacy are currently being evaluated by regulatory authorities. The interim analysis at 56 weeks in the ECZTEND trial (NCT03587805) showed tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) demonstrated long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms.1 Patients who had enrolled in pivotal Phase 3 trials ECZTRA 1 and 2 who continued into ECZTEND w

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD ® Use During the COVID-19 Pandemic23.4.2021 15:11:00 CEST | Press release

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. The data were presented at the 2021 American Academy of Neurology (AAN) Annual Meeting that was held virtually 17-22 April 2021. In the MAGNIFY-MS study, reduction of memory B cells occurred as early as one month after MAVENCLAD initiation with lowest levels sustained for up to 12 months, while naïve B cells, which are typically required for the generation of antibody responses following vaccination, began recovering immediately. Previously shared data from MAGNIFY-MS indicated that patients receiving MAVENCLAD are able to mount responses to influenza and varicella zoster vaccines, irrespec

Xsolla Offers Exit Strategies to Game Studios for Exit Advising and Planning23.4.2021 15:00:00 CEST | Press release

Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has announced Xsolla Exit Strategies. The new service will connect development studios with financial and transaction advisors, guiding them through the process of selling their game property or studio, from due diligence preparation to exiting. The unveil of Xsolla Exit Strategies comes full circle from Xsolla Funding Club, launched March 2019, which provides matchmaking between vetted game projects and qualified investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005013/en/ Let Xsolla Exit Strategies match you with a financial and transaction advisor to help meet your exit goals. (Graphic: Business Wire) The gaming industry continues to flourish as demand is high for strategic partnerships and acquisitions for both game companies

Wipro Achieves Google Cloud Partner Specialization in Application Development23.4.2021 14:33:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has achieved the Google Cloud Partner Specialization in application development. This marks the fourth Partner Specialization badge that Wipro has received from Google Cloud, following recognition for outstanding cloud security, migration, and work transformation. This specialization demonstrates Wipro’s capabilities across multiple areas as a Google Cloud SI partner. As a trusted Google Cloud partner, Wipro can help customers leverage the best of Google Cloud platform as they develop and manage cloud-native business applications, enabling faster time to market, increasing scalability of applications and integrating them with external and internal systems in the IT landscape. This specialization will allow Wipro’s team of certified professionals to accelerate the customer modernization journey, increase agility and adapta

LEO Pharma Receives Positive CHMP Opinion of Adtralza ® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis23.4.2021 13:59:00 CEST | Press release

LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The CHMP positive opinion is one of the final steps before the European Commission makes its decision on the Marketing Authorization Application for use of Adtralza, an investigational therapy in clinical development, throughout the European Union. This final decision is expected in the coming months and if authorized, Adtralza will be the first fully human, monoclonal antibody available to specifically target the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms. Adtralza specifically targets IL-13 with high affinity and is developed to improve the symptoms of atopic derma

Schlumberger Announces First-Quarter 2021 Results23.4.2021 12:50:00 CEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the first-quarter 2021. First-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2021 Dec. 31, 2020 Mar. 31, 2020 SequentialYear-on-yearRevenue* $5,223 $5,532 $7,455 -6% -30% Income (loss) before taxes - GAAP basis $386 $471 $(8,089) -18% n/m Net income (loss) - GAAP basis $299 $374 $(7,376) -20% n/m Diluted EPS (loss per share) - GAAP basis $0.21 $0.27 $(5.32) -22% n/m Adjusted EBITDA** $1,049 $1,112 $1,347 -6% -22% Adjusted EBITDA margin** 20.1% 20.1% 18.1% 0 bps 203 bps Pretax segment operating income** $664 $654 $776 1% -14% Pretax segment operating margin** 12.7% 11.8% 10.4% 88 bps 230 bps Net income, excluding charges & credits** $299 $309 $351 -3% -15% Diluted EPS, excluding charges & credits** $0.21 $0.22 $0.25 -5% -16% Revenue by Geography International $4,211 $4,343 $5,225 -3% -19% North America* 972 1,167 2,180 -17% -55% Other 40 22 50 n/m n/m $5,223 $5,532 $7,455 -6% -30%